GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine

Journal of Neurochemistry

Volumn 127, Issue 2, 2013, Pages 177-186

  Horton, David B ^a   Nickell, Justin R ^a   Zheng, Guangrong ^a   Crooks, Peter A ^a   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

Author keywords

dopamine release; dopamine uptake; methamphetamine; neuropharmacology; pharmacotherapy; VMAT2

Indexed keywords

3 [2,6 DI(4 METHOXYPHENETHYL)PIPERIDIN 1 YL]PROPANE 1,2 DIOL; DRUGS USED IN THE TREATMENT OF ADDICTION; GZ 793A; METHAMPHETAMINE; RESERPINE; TETRABENAZINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE;

DOPAMINE RELEASE; DOPAMINE UPTAKE; METHAMPHETAMINE; NEUROPHARMACOLOGY; PHARMACOTHERAPY; VMAT2;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; LOBELINE; MALE; METHAMPHETAMINE; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SYNAPTIC VESICLES; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84885394848     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12371     Document Type: Article

References (41)

1. Alvers K. M., Beckmann J. S., Zheng G., Crooks P. A., Dwoskin L. P., and, Bardo M. T., (2012) The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology 224, 255-262.
2. Beckmann J. S., Denehy E. D., Zheng G., Crooks P. A., Dwoskin L. P., and, Bardo M. T., (2012) The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology 220, 395-403.
3. Damaj M. I., Patrick G. S., Creasy K. R., and, Martin B. R., (1997) Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282, 410-419.
4. Darchen F., Scherman D., and, Henry J. P., (1989) Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28, 113-122.
5. Di Chiara G., and, Imperato A., (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274-5278.
6. Dwoskin L. P., and, Crooks P. A., (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63, 89-98.
7. Eisenhofer G., Kopin I. J., and, Goldstein D. S., (2004) Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann. N. Y. Acad. Sci. 1018, 224-230.
8. Fischer J. F., and, Cho A. K., (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208, 203-209.
9. Galli A., Blakely R. D., and, DeFelice L. J., (1996) Norepinephrine transporters have channel modes of conduction. Proc. Natl Acad. Sci. USA 6, 8671-8676.
10. Gnegy M. E., (2003) The effect of phosphorylation on amphetamine-mediated outward transport. Eur. J. Pharmacol. 280, 83-91.
11. Harrod S. B., Dwoskin L. P., Crooks P. A., Klebaur J. E., and, Bardo M. T., (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 280, 1432-1444.
12. Harrod S. B., Dwoskin L. P., Green T. A., Gehrke B. J., and, Bardo M. T., (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology 165, 397-404.
13. Horton D. B., Siripurapu K. B., Zheng G., Crooks P. A., and, Dwoskin L. P., (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J. Pharmacol. Exp. Ther. 339, 1-12.
14. Jones R,. (2007) Double-blind, placebo-controlled, cross-over assessment of intravenous methamphetamine and sublingual lobeline interactions. NCT00439504. Clinical Trials.gov.
15. Kenakin T. P., (1993) Pharmacologic Analysis of Drug-Receptor Interaction, 2nd edn. Raven Press, New York.
16. Kenakin T. P., (2006) A Pharmacology Primer, Second Edition: Theory, Application, and Methods, 2nd edn. Academic Press, San Diego.
17. Kukkonen A., Perakyla M., Akerman K. E. O., and, Nasman J., (2004) Muscarinic toxin 7 selectivity is dictated by extracellular receptor loops. J. Biol. Chem. 279, 50923-50929.
18. Meyer A. C., Horton D. B., Neugebauer N. M., Wooters T. E., Nickell J. R., Dwoskin L. P., and, Bardo M. T., (2011) Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology 61, 849-856.
19. Miller D. K., Crooks P. A., Zheng G., Grinevich V. P., Norrholm S. D., and, Dwoskin L. P., (2004) Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J. Pharmacol. Exp. Ther. 310, 1035-1045.
20. 3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol. Pharmacol. 30, 252-257.
21. Neugebauer N. M., Harrod S. B., Stairs D. J., Crooks P. A., Dwoskin L. P., and, Bardo M. T., (2007) Lobelane decreases methamphetamine self-administration in rats. Eur. J. Pharmacol. 571, 33-38.
22. Nickell J. R., Krishnamurthy S., Norrholm S., Deaciuc A. G., Siripurapu K. B., Zheng G., Crooks P. A., and, Dwoskin L. P., (2010) Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 332, 612-621.
23. 3H]dopamine uptake at the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 336, 724-733.
24. Partilla J. S., Dempsey A. G., Nagpal A. S., Blough B. E., Baumann M. H., and, Rothman R. B., (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 319, 237-246.
25. Peter D., Liu Y., Brecha N., and, Edwards R. H., (1995) The transport of neurotransmitters into synaptic vesicles. Prog. Brain Res. 105, 273-281.
26. Pifl C., Drobny H., Reither H., Hornykiewicz O., and, Singer E. A., (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368-373.
27. Pletscher A., (1977) Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules. Br. J. Pharmacol. 59, 419-424.
28. Rudnick G., (1990) Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29, 603-608.
29. Scherman D., and, Henry J. P., (1984) Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25, 113-122.
30. Schuldiner S., Steiner-Mordoch S., Yelin R., Wall S. C., and, Rudnick G., (1993) Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 1227-1231.
31. Sonders M. S., and, Amara S. G., (1996) Channels in transporters. Curr. Opin. Neurobiol. 6, 294-302.
32. Sonders M. S., Zhu S. J., Zahniser N. R., Kavanaugh M. P., and, Amara S. G., (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17, 960-974.
33. Substance Abuse and Mental Health Services Administration. (2011) Results from the 2010 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-41, HHS Publication No. SMA 11-4856 Findings). Rockville, MD.
34. Sulzer D., and, Rayport S., (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808.
35. Sulzer D., Sonders M. S., Poulsen N. W., and, Galli A., (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406-433.
36. 3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280, 1432-1444.
37. 3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71, 258-265.
38. Tucek S., and, Proska J., (1995) Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 16, 205-212.
39. Wise R. A., and, Bozarth M. A., (1987) A psychomotor stimulant theory of addiction. Psychol. Rev. 94, 469-492.
40. Wooters T. E., Smith A. M., Pivavarchyk M., Siripurapu K. B., McIntosh J. M., Zhang Z., Crooks P. A., Bardo M. T., and, Dwoskin L. P., (2011) bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br. J. Pharmacol. 163, 346-357.
41. Yelin R., and, Schuldiner S,. (2002) Vesicular neurotransmitter transporters pharmacology, biochemistry and molecular analysis, in Contemporary Neuroscience: Neurotransmitter Transporters: Structure, Function, and Regulation (, Reith M. E. A., ed.), pp. 313-354. Humana Press, Totowa, NJ.